Summary
In male mice of strains C3H and C57BL/6 an experimental immune-mediated diabetes can be induced by multiple low doses of streptozotocin. The delay and partial suppression of hyperglycaemia after anti-I-A monoclonal antibody administration was dose dependent. Even saturation levels of anti-I-A did not cause complete protection from diabetes development. Administration of anti-I-E monoclonal antibody also significantly delayed the onset of hyperglycaemia. Surprisingly, the combined treatment with anti-I-A and anti-I-E did not result in better protection from diabetes. Thus, there is an I-A and I-E independent component of the disease. Furthermore, there is no restriction to either I-A or I-E. Anti-I-A was only effective when given at the beginning of the experiment, which implies that I-A molecules have a primary function during the induction of diabetes. The contribution of I-J to the disease process is different. Administration of a polyspecific alloantiserum to I-J almost completely prevented hyperglycaemia. Injections of monospecific antibodies to I-J determinants enhanced hyperglycaemia, especially when given after the induction of diabetes. This indicates that I-J is involved in initial as well as in later stages of the disease process.
Article PDF
Similar content being viewed by others
References
Steinberg AD, Santoro TJ (1984) Anti-Ia antibodies: a revolutionary therapy for immune-mediated diseases? Immunol Today 5: 13–14
Waldor MK, Sriram S, McDevitt HO, Steinman L (1983) In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc Natl Acad Sci USA 80: 2713–2717
Christadoss P, Lindstrom J, Talal N (1983) Cellular immune response to acetylcholine receptors in murine experimental autoimmune myasthenia gravis: inhibition with monoclonal anti-I-A antibodies. Cell Immunol 81: 1–8
Steinman L, Rosenbaum JT, Sriram S, McDevitt HO (1981) In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci USA 78: 7111–7114
Sriram S, Steinman L (1983) Anti-I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to Ir genes. J Exp Med 158: 1362–1367
Adelmann NE, Watling DL, McDevitt HO (1983) Treatment of (NZB × NZW)F1 disease with anti-I-A monoclonal antibodies. J Exp Med 158: 1350–1355
Wooley PH, Luthra HS, Lafuse WP, Huse A, Stuart JM, David CS (1985) Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera. J Immunol 134: 2366–2374
Vladutio AO, Steinman L (1987) Inhibition of experimental autoimmune thyroiditis in mice by anti-I-A antibodies. Cell Immunol 109: 169–180
Kiesel U, Kolb H (1983) Suppressive effect of antibodies to immune response gene products on the development of low-dose streptozocin-induced diabetes. Diabetes 32: 869–871
Bonnevie-Nielsen V, Lernmark Å (1986) An H-2 allo-antiserum preserves β-cell function in mice made diabetic by low-dose streptozocin. Diabetes 35: 570–573
Like AA, Rossini AA (1976) Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193: 415–417
Kolb H (1987) Mouse models of insulin dependent diabetes — low dose streptozotocin induced diabetes and non obese diabetic (NOD) mice. Diabetes Metab Rev 3: 751–778
Kiesel U, Kolb H (1982) Low-dose streptozotocin-induced autoimmune diabetes is under the genetic control of the major histocompatibility complex. Diabetologia 23: 69–71
Kiesel U, Falkenberg FW, Kolb H (1983) Genetic control of low-dose streptozotocin-induced autoimmune diabetes in mice. J Immunol 130: 1719–1722
Rossini AA, Williams RM, Appel MC, Like AA (1978) Complete protection from low-dose streptozotocin-induced diabetes in mice. Nature 276: 182–184
Kiesel U, Oschilewski M, Oschilewski U, Stünkel K, Opitz U, Kolb H (1984) Role of helper and suppressor lymphocytes and of macrophages in multiple dose streptozotocin-induced autoimmune diabetes. Diabetologia 27: 296 (Abstract)
Kantwerk G, Cobbold S, Waldmann H, Kolb H (1987) L3T4 and Lyt2 cells are both involved in the generation of low-dose streptozotocin induced diabetes in mice. Clin Exp Immunol 70: 585–592
Herold KC, Montag AG, Fitch FW (1987) Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozocin. Diabetes 36: 796–801
Kanno M, Kobayashi S, Tokuhisa T, Takei I, Shinohara N, Taniguchi M (1981) Monoclonal antibodies that recognize the product controlled by a gene in the I-J subregion of the mouse H-2 complex. J Exp Med 154: 1290–1304
Dayer-Metroz MD, Kimoto M, Izui S, Vassalli P, Renold AE (1988) Effect of helper and/or cytotoxic T-lymphocyte depletion on low-dose streptozocin-induced diabetes in C57BL/6J mice. Diabetes 37: 1082–1089
Kolb-Bachofen V, Epstein S, Kiesel U, Kolb H (1988) Low-dose streptozocin-induced diabetes in mice. Electron microscopy reveals single-cell insulitis before diabetes onset. Diabetes 37: 21–27
Bolaffi JL, Nowlain RE, Cruz L, Grodsky GM (1986) Progressive damage of cultured pancreatic islets after single early exposure to streptozocin. Diabetes 35: 1027–1033
Campbell IL, Oxbrow L, Koulmanda M, Harrison LC (1988) IFN induces islet cell MHC antigens and enhances autoimmune, streptozocin-induced diabetes in the mouse. J Immunol 140: 1111–1116
Boitard C, Michie S, Serrurier P, Butcher GW, Larkins AP, McDevitt HO (1985) In vivo prevention of thyroid and pancreatic autoimmunity in the BB rat by antibody class II major histocompatibility complex gene products. Proc Natl Acad Sci USA 82: 6627–6631
Benacerraf B, McDevitt HO (1972) The histocompatibility linked immune response genes. Science 175: 273–279
Buus S, Sette A, Colon SM, Miles C, Grey HM (1987) The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 235: 1353–1358
Offner H, Brostoff S, Vandenbark AA (1986) Antibodies against I-A and I-E determinants inhibit the activation and function of encephalitogenic T-lymphocyte lines. Cell Immunol 100: 364–373
Jaureguiberry B, Liao L, Kuchroo V, Dorf ME, Diamond B (1988) Monoclonal anti-idiotypic antibodies to an I-J interacting molecule inhibit suppression in an H-2 restricted way. J Immunol 140: 3286–3289
Tada T, Takemori T, Okumura K, Nonaka M, Tokuhisa T (1978) Two distinct types of helper T cells involved in the secondary antibody response: independent and synergistic effects of Ia− and Ia+ helper T cells. J Exp Med 147: 446–458
Sumida T, Sado T, Kojima M, Ono K, Kamisaku H, Taniguchi M (1985) I-J as an idiotype of the recognition component of antigen-specific suppressor T-cell factor. Nature 31: 738–741
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kiesel, U., Oschilewski, M., Taniguchi, M. et al. Modulation of low-dose streptozotocin-induced diabetes in mice by administration of antibodies to I-A, I-E and I-J determinants. Diabetologia 32, 173–176 (1989). https://doi.org/10.1007/BF00265090
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00265090